New Anti-Angiogenesis Target: a Dual-Ligand Receptor
R. Clark, M. Pratt
Boston University, US
angiogenesis, cancer, VEGF
The present application is directed to the identification of mutations and/or polymorphisms in the Dual Endothelin-l/Angiotensin II Receptor (Dear) that indicate susceptibility to, or show current affliction with, hypertension. Additionally, the present invention discloses methods for the modulation of angiogenesis via the regulation of Dear.
Nanotech 2008 Conference Program Abstract